South Korea's pharmaceutical giant Celltrion Inc. said Monday that it has received approval from Canadian health authorities ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has begun commercial operation of its third manufacturing plant in the country. The plant in Incheon, just west of Seoul, ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

Celltrion today presented additional data from a Phase III randomized controlled trial (RCT) for CT-P41, a biosimilar candidate referencing PROLIA®/XGEVA® (denosumab) in postmenopausal women ...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

With a production capacity of 60,000 liters, the new plant boosts Celltrion’s total biopharmaceutical manufacturing capacity to 250,000 liters when combined with its first plant’s 100,000 ...

Korean drugmaker Celltrion plans to achieve annual sales of 5 trillion won ($3.58 billion) next year, driven by the growth of ...

Biopharmaceutical company Celltrion said Thursday that it began the commercial operation of its third plant for drug substances. According to the biotech firm, it recently completed the validation ...

As we previously reported, this August the European Commission granted approval for Celltrion’s STELARA biosimilar, STEQEYMA. Earlier this month, Celltrion launched STEQEYMA in both Germany and ...